Novartis IP Expert Slams Rival's Royalties Estimate At Trial

By Dorothy Atkins (July 19, 2021, 10:05 PM EDT) -- During a California federal jury trial Monday over claims Novartis owes a Daiichi Sankyo subsidiary royalties for infringing its skin cancer patents, Novartis' patent damages expert criticized the unit's $47.2 million royalties estimate and testified that any royalties should be $1.89 million at most.

James Malackowski of patent capital company Ocean Tomo LLC took the stand during the second week of an in-person jury trial that kicked off July 12 over Plexxikon Inc.'s claims that Novartis owes royalties for selling a skin cancer drug called Tafinlar that allegedly infringes two Plexxikon patents.

Plexxikon's patents cover molecular compounds that use the same mechanism...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!